Good day, and thank you for standing by. Welcome to Bayer's investor and analyst conference call on the third quarter 2022 results. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question during the session, you will need to press star one and one on your telephone. You will then hear an automated message advising your hand is raised. Please be advised that today's conference is being recorded. I would now like to hand the conference over to Oliver Maier, Head of Investor Relations of Bayer AG. Please go ahead. Great. Thank you so much, Heidi. Good afternoon, and thanks to everybody for joining us today. I would like to welcome all of you to our third quarter 2022 conference call. In order to ensure good audio quality, we kindly ask you to use a speaker and a landline instead of a headset or a cell phone, for example. With me on the call today are Werner Baumann, our CEO, and Wolfgang Nickl, our CFO, and the businesses are represented by the responsible management board members for the Q&A session. Werner will begin today's call with an overview of the key developments and achievements, and Wolfgang will then cover the performance of our businesses and outlook before we open up the Q&A session. As always, I would like to start the call today by drawing your attention to the cautionary language that is included in our safe harbor statement, as well as in all the materials that we have distributed, today. Please also note that all net sales growth figures we reference in this call are on a currency and portfolio-adjusted basis, if not mentioned differently. With that, I'll hand it over to you, Werner. Yeah. Thanks, Oliver, and good morning, and thanks for joining us today. I would like to welcome all of you to our third quarter 2022 conference call. After a very successful first half of the year, we raised our financial guidance for the full year in August. With the third quarter results, we delivered sustained strong operational performance to put us fully on track to achieve our targets for 2022, as well as investment and progress in our pipeline, which are important for the next years to come. While we are benefiting from some tailwinds, I'd like to point out that this year's performance and progress on the innovation side are based on the strong execution of our long-term strategy for growth. Amid increasing pressure on global supply chains and accelerating inflation, we were able to grow our top line and increase our earnings in the third quarter across all businesses on top of a tough comparable prior year base. Our Crop Science division delivered another record sales quarter based on the continued strength of our herbicides business and a strong start to the season in Latin America. On a year-to-date basis, Crop Science grew sales by 17% at an industry-leading profitability with more than 30% EBITDA margin before special items. This reflects a significant margin increase year-over-year with efficiency measures and pricing more than offsetting cost inflation. Pharmaceuticals grew 3% year-to-date with Eylea delivering a 10% increase, whereas Xarelto continues to be impacted by volume-based procurement in China and loss of exclusivity in Brazil. Our new product, Nubeqa, almost doubled sales in the first nine months of 2022. For the first time, our launch assets, Nubeqa and Kerendia, were the key growth drivers, delivering more than half of the division's quarterly growth. In Consumer Health, we increased top line by 9% year to date, particularly driven by allergy and cold with +24%. We are off to a good start with the launch of Astepro, which marks the first of its kind allergy solution for U.S. consumers as a steroid-free antihistamine spray that works much faster than what is currently on the market. On group profitability, we have been able to compensate accelerating inflation with efficiency measures in all divisions and, of course, active pricing management, predominantly in Crop Science and Consumer Health, while Pharma reimbursement continues to be under pressure. We expect the full cost inflation effects across the value chain to actually materialize only next year. Beyond cost mitigation measures, we also continue to manage our direct and indirect exposure around energy supply as well as supply chain stability in a broader sense. For our operations in Germany, we should be independent from Russian gas supplies by the end of this year. Nevertheless, we are observing continued pressure on supply chains in general and could have grown our business even more this year without those headwinds. Looking ahead into next year, the stability of our supply chains will continue to be of critical importance for us. We are building further safety stocks as we speak and work intensively with our suppliers and contract manufacturers towards higher product availability and more stable supply chains. Our focus on health and nutrition has proven to increase our resilience in times of crisis. After an already strong 2021, we are on track for a very, very good 2022. That's evident beyond our operational performance as we continue to deliver on important innovation milestones. In pharmaceuticals, we have achieved key pipeline advancements in quarter three that we had on our agenda for this year, which will underpin our acceleration of long-term growth beyond 2024. First, we made significant progress and paved the way forward for our Factor XI inhibitor development program. With the phase II study data of all of our three Factor XI candidates at hand, we decided to take our orally administered compound, asundexian, into phase II in atrial fibrillation, as well as secondary stroke prevention. Provided a successful trial outcome, asundexian could be in the market as early as 2026, and thus potentially dovetailing into Xarelto's loss of exclusivity in Europe by then. As we own the full global rights to asundexian, it could also provide a key cornerstone in our ambition to further expand our footprint in the U.S. With the focus of our Factor XI inhibitor program now being on asundexian and in line with a disciplined approach towards resource allocation, we have also taken the decision to discontinue the development of our two parenteral drug candidates, fesomersen and osocimab. Second, we've also made significant progress on our marketed assets. For our ophthalmology franchise, very strong study data from the two phase II trials, PULSAR and PHOTON, showed that the vast majority of our patients with diabetic macular edema and age-related macular degeneration could be treated with aflibercept 8 mg every 16 weeks while benefiting from the same safety and efficacy profile of the lower dose Eylea. These results will now give patients and physicians the opportunity to effectively lower the number of annual treatments with aflibercept by up to 50%, thus providing strong arguments for higher convenience, adherence to therapy, and improved patient outcomes. Our goal is to have aflibercept 8 mg launched in our major territories already by 2024. We expect its strong value proposition to be a key pillar in defending the leading market position of this product also beyond the expiry of the active ingredient patent, which in most of our markets will be in 2025. Finally, we also received important U.S. label expansions of our launch products from the FDA. Following its recent approval in the metastatic hormone-sensitive setting, our innovative prostate cancer medicine, Nubeqa, is now available for patients in the mid and the late stage of the disease. Moreover, the label of Kerendia has been expanded to also include the results from the phase III FIGARO-DKD study. This effectively complements the use of Kerendia to patients who are at an earlier stage of chronic kidney disease with type 2 diabetes. In that context, we were also pleased to see that the KDIGO suggested to add Kerendia to the SGLT-2 inhibitors for the treatment of patients with chronic kidney disease and type 2 diabetes just two weeks ago. For Crop Science, we recently announced our agreement with Ginkgo Bioworks to further bolster our position in biologicals through a multi-year strategic partnership to accelerate research and development of biological products. This includes the continued advancement of Joyn Bio's innovative nitrogen fixation platform and the exclusive rights to this technology. For Consumer Health, the launch of Astepro in the U.S. OTC market is progressing well and will form a strong base for next year's allergy season. It's actually a great example on how our businesses complement each other as we have leveraged on our pharmaceutical regulatory capabilities to make the switch successful. Based on this experience, we are confident to realize more of these switches going forward to drive further growth. We also made further progress in streamlining our portfolio and focusing on strategically relevant businesses. We successfully closed the sale of Environmental Science Professional business to Cinven beginning of October, and only last week, we also closed the divestment of our testosterone therapy, Nebido, to Grünenthal. Our investments move also beyond innovation. In early October, USAID announced Bayer as the anchor partner to their AGRI-Ukraine initiative, highlighting our planned investment of approximately EUR 35 million to boost the capacity of our corn seed processing facility in Pochuiky. It's the largest of its kind in Ukraine and actually one of the largest in Europe. Finally, we continue to progress our ESG efforts and transparency and recently issued the first sustainability progress report of our Crop Science division. In addition, MSCI has upgraded our ESG rating from B B to A in August. This rating upgrade followed the removal of the GMO red flag and is another very important milestone improving our ESG profile. Wolfgang will now provide more specific insights into the performance of our businesses and our outlook. With that, I hand it over to you, Wolfgang. Well, thank you, Werner, and welcome also from my end to everybody on the call. In the third quarter, group sales increased by 6% to EUR 11.3 billion, with growth contributions coming from all divisions, most notably from value-based pricing in Crop Science. Group EBITDA before special items increased by 17% year-over-year to EUR 2.5 billion. This led to a margin before special items of 21.7%. When looking at the impact from foreign exchange rates, we saw continued tailwind on revenue and a headwind on earnings before special items. The latter stems from seasonally low revenues with high cost base in U.S. dollar and the fact that we adjusted the reporting of the negative year-to-date currency impact of the Turkish lira and Argentine peso on earnings. I will get back to the year-to-date FX impact later, which provides a more representative view for the full year. Core earnings per share came in at EUR 1.13, which is 8% above the previous year. This includes a negative development from the core financial result of EUR 219 million, mainly stemming from higher interest costs and non-cash relevant fair value changes for some of our balance sheet positions. In the third quarter, our core tax rate increased to 25.9%, which leads to 22.4% on a year-to-date basis. This is in line with our 23% guidance for the full year. Our free cash flow amounted to EUR 1.7 billion, which is 11% below prior year. The reduction is mainly driven by cost inflation in inventories and phasing of rebate payments, which could not be fully offset by lower settlement payments and significant growth in earnings. Our net financial debt decreased by roughly EUR 700 million to EUR 35.9 billion at the end of the third quarter. Positive cash flow contributions was partially offset by a negative effect from the strong U.S dollar. Please note that the net proceeds from the closing of the Environmental Science Professional divestment were received at the beginning of October and will be reflected in the Q4 results. Let's now look more specifically at the drivers of divisional performance in the third quarter. Crop Science delivered very good Q3 results, with 8% sales growth and a 34% increase in EBITDA before special items. Q3 is typically the smallest sales and earnings quarter for Crop Science in our fiscal year. Herbicides continued the trend from the first half of this year with more than 45% sales growth, which was largely driven by strong pricing for our glyphosate-based products. We also saw a strong start to the season in Latin America, with sales growth above 30% or approximately EUR 500 million. Herbicide sales more than doubled in corn, soybeans and insecticides, all delivered mid-teens percentage sales growth in the region. For corn, we grew our seed share globally for the 2022 crop year, despite lower planted acres in the United States. The sales decrease of 16% in the third quarter is due to higher returns because of the decline in acres planted, as well as slightly lower licensing revenues. This more than offset growth in LatAm in the mid-teens. In soybeans, sales declined by 8% due to higher returns in the U.S., but more than offset the growth in LatAm. While we did see some decline in seeds and trait share in the U.S., we held our number one trait position in both the U.S. and Brazil, reaching greater than 50% and greater than 80% of acres planted respectively. We also continue to upgrade our footprint with our recently launched XtendFlex and Intacta to extend soybean trait offerings. These next-generation traits are foundational to delivering the more than EUR 2 billion of seed and trait licensing revenue we earn annually. On the bottom line, earnings before special items grew to EUR 629 million, representing a margin of 13.4% and an improvement of 120 basis points over prior year. The improved pricing and mix from the introduction of new products, as well as savings from the ongoing efficiency programs, more than offset lower volumes and cost inflation of roughly EUR 245 million, particularly in cost of goods sold. Our Pharma business increased sales by 3% and EBITDA before special items by 15%. As Werner pointed out, our launch assets, Nubeqa and Kerendia, were main growth drivers on the top line this quarter. A similarly strong contribution also came from our IUD franchise, with double-digit growth driven by phasing and recovery from COVID-19 related effects. Once again, Eylea continued to exceed our expectations, delivering a 4% increase in the third quarter. Top line increased across all regions, with the strongest contributions coming from Europe and China. Sales of Xarelto showed an 8% decline in the third quarter. As expected, key driver, again, was the impact from volume-based procurement in China, which should now be largely absorbed on a year-on-year basis. In addition, the loss of exclusivity in Brazil weighed on sales. Sales also benefited from contract development and manufacturing milestones from our cell and gene and chemoproteomics platforms. Looking at the bottom line, our earnings before special items increased to EUR 1.5 billion and a margin of 31.7%, which is 160 basis points above the prior year. This includes the effect from the above-mentioned milestones as well as gains from the sale of non-strategic businesses. We also reallocated spend and focused our R&D and marketing investments. Let's finally look at the performance of our Consumer Health business. In Q3, we continued our strong growth trajectory across all regions with sales growth of 4% on top of a high prior year comparable and a 9% increase in earnings. Demand remained high for our cough and cold products, which grew due to a higher number of cold incidences. Sales also increased for our allergy portfolio, and we note positive momentum for our Astepro launch in the United States OTC market. In total, this led to 17% growth for the allergy and cold category. For Nutritionals, we saw the expected normalization in line with market development, with an 8% sales decline in the quarter on a higher level in absolute terms. Strong sales growth translated to an increase in earnings before special items to EUR 336 million, whereas margin came in 120 basis points below previous year at 21.7%, primarily driven by higher commercial investments, in particular for the launch of Astepro. Let's now look at our year-to-date performance. Let me discuss the main drivers of our top-line growth first. Our total year-to-date sales growth for the group is largely driven by price in Crop Science and Consumer Health. Pharma, on the other hand, recorded a negative pricing impact. For Crop Science, pricing for glyphosate-based herbicide contributed nearly EUR 1.9 billion in the first nine months. We maintained a brand premium over generics sourced out of China, where supply was tight. Market prices in Q3 were down when compared to the first half of the year, and going forward we expect further normalization in Q4 and next year. Most importantly, besides the glyphosate dynamics, we are also delivering on mid-single-digit percentage price improvements in corn, fungicides, insecticides, and other herbicides to round out the growth in Crop Science this year. For the 2023 season, we already announced our branded seed pricing for corn and soy for the U.S. and for corn in Europe, and expect to deliver on average low double-digit percentage price increases. For Consumer Health, we saw broad-based pricing growth of 6% across categories. At the same time, we start observing selective price elasticity on demand, while consumers continue to value superior brand benefits of Bayer. In Pharmaceuticals, growth in the first nine months of the year was entirely volume driven. We saw overall a negative pricing effect from volume-based procurement for Xarelto in China and largely fixed pricing in general. So far, we have not seen substantial impact from volume-based procurement for Adalat, which we expect to start in Q4, fully materializing next year. Looking at the bottom line, as mentioned earlier, all our divisions are affected by significant cost inflation for input materials, energy, freight, warehousing, and personnel. The cost inflation effect is particularly strong in Crop Science, with around 4% of net sales or approximately EUR 700 million. Pharma is impacted by EUR 450 million, and Consumer Health by around EUR 180 million year to date compared to previous year. We expect the full cost inflation effects across the value chain to materialize next year, and we'll continue to actively manage these impacts with efficiencies and pricing where possible. Another driver are the exchange rates. Year to date, we benefited from material tailwinds of about EUR 2.4 billion in sales and roughly EUR 290 million in earnings before special items. This leads to a year-to-date margin dilution of 110 basis points. We expect margin dilution to come down to about 70 basis points by the end of the year based on our latest estimate, which uses September month-end spot rates. With the strong year-to-date performance, we are well on track to achieve our full year growth and P&L guidance for the group in 2022. For Crop Science and Consumer Health, we see some upside potential, whereas targets remain challenging in Pharma. We confirm our group P&L outlook and core EPS guidance upgraded in August, now including the effect from the Environmental Science divestment. We have increased our free cash flow guidance by EUR 500 m illion to approximately EUR 3 billion at constant currencies due to lower than anticipated net settlement payments. We've also updated our net financial debt guidance for the higher free cash flow, as well as the closing of the Environmental Science Professional divestment. Net debt is now expected to be at approximately EUR 31 billion at constant currencies at year-end. In the column on the right, you find the updated foreign exchange estimate at the latest rates as of the end of September. The latest changes now lead to an estimate of approximately EUR 3.5 billion tailwind in net sales and a dilutive effect on margin of 70 basis points, as I mentioned before. Let me also note that the strong U.S. dollar will increase net financial debt by about EUR 2 billion when using end of September exchange rates again. With that, I'll hand the call back over to you, Oliver, to start us on the Q&A, please. Great. Thanks, Wolfgang. Thanks, Werner, for the overview. Before we begin, I always like to remind you to keep your questions to about two per person so that we are able to take as many questions, from as many participants as possible. With that, Heidi, I think we can open up for the Q&A session please. Thank you. As a reminder, to ask a question, you will need to press star one and one on your telephone and wait for your name to be announced. Your first question comes from the line of Michael Leuchten from UBS. Please ask your question. Oh, thank you very much. It's Michael Leuchten from UBS. Just, thank you for all the details on the moving parts as we think about 2023. I was just wondering if you Could try to put that together for us. It sounded like your most important variables as to where the margin Crop Science can go in 2023 is really down to glyphosate pricing, given the price increases that you pointed to on the portfolio. And related to that, are you able to absorb the inflation costs in the Crop Science business with those price increases or is the inflationary pressure beyond that? Thank you. I can probably start and this Wolfgang and Werner can then supplement. I'm happy to repeat some of the vectors that described it. As a safe harbor, we're giving you some vectors to orient yourself, but we're not giving specific guidance today for 2023. I mean, they're pretty volatile in this environment and we'll do that in Q1 as usual. I think the components for Crop Science and others can chime in is certainly the pricing. I mean, we have seen in the first nine months glyphosate pricing at EUR 1.9 billion above the same period of the prior year. I think Q3 was lower than what we saw in the first half of the year. We expect the pricing to further normalize into Q4 and next year. Of course, what we are trying to do is offset some of this with price increases in other areas. I gave you the soy and corn example for the U.S. For next year and in corn for Europe, where we have double-digit price increases. Inflation is a big deal, that's why we pointed out what it is for the first nine months. One of the important things, Michael, that you need to consider is that some of the inflation is still showing in inventory. You've probably seen that when you look at our cash flow statements, and that's just simply what happens when you do first in, first out, for the earlier purchased, cheaper inventory gets consumed in the P&L earlier, and then next year it gets a bit more burdened. Then I would also like to point out, and I'm sure you have that in your models, as well, Michael, that obviously we are super happy that we successfully sold our Environmental Science business at a very favorable rate. You may recall that EUR 600 million business in top line was about 1/3 of that in EBITDA. You can do the math what that does because this year there are only three months missing, but in the next year there's a whole year missing. That's a quick summary of the Crop Science-related piece, but others, Rodrigo or Werner, you can chime in, please. Yeah. Maybe I quickly add to what Wolfgang said. Let me start out by saying what I said in my introductory remarks. We are enjoying a very strong 2022 that has brought us essentially into the range of our 2024 guidance. Some of that is, of course, driven by the significant cyclical support that we get out of our Crop Science business. As Wolfgang already pointed out, some of it is not there to stay at the level that we are seeing in 2022. With average prices of glyphosate, which are, you know, quite a bit higher than what we see in quarter three, and in all likelihood, see a little bit lower even in quarter four than entering into 2023. That is an important vector to watch out for. Secondly, I think pricing and Rodrigo can comment on that in more detail. Pricing has been taken quite, you know, substantially across the entire crop portfolio based on the cost increases that we see across the portfolio. This is not only a glyphosate story to be very clear on that. That is true for 2022 and that is also true for the price cuts that Wolfgang already referred to going into 2023. You have more of the same in pricing upwards in order to absorb inflation and then protect margin in our Consumer business. Last but not least, before I hand it over to Rodrigo, the thing is, of course, very different in pharma. We see, you know, the same inflationary pressure on the cost of goods side with relatively low cost of goods, a little bit lower, but then we have also salary and wage inflation that is going to hit fully in 2023. While at the same time, we cannot price up because we happen to be, you know, in regulatory systems and on top of that, do have, you know, further, you know, top line effects from the Xarelto LOEs in different countries, and volume-based procurement, which has been with us for certainly 2021 and 2022 on Xarelto and, now with Adalat going into 2023, one very important product that is going to be affected as well. Those are the things that have to be kept in mind that we have, you know, in terms of pricing, also different businesses with different exposures, to the extent that they can, you know, carry through inflation with higher pricing. With that, Rodrigo, please. No, Michael. Just to complement, Werner and Wolfgang, they did a great job talking about the pricing efforts that we are doing. I think there just one information to complement is our efficiency programs, right? We are also working a lot on that one. Just to give you a number for 2022, by the end of this year, we are expecting EUR 200 million of savings on our efficiency programs. When you think about 2023, of course, we're gonna continue to do a lot of work with our supply team in terms of cost management, efficiency programs, supply resilience to help us. That equation of addressing inflation through pricing and our efficiency programs to help us drive what we planned for the next years. Thank you. Thank you, Michael. Thank you. We will take our next question. The question comes from the line of Richard Vosser from JPMorgan. Please go ahead. Your line is open. Hi. Thanks very much. Two questions, please. One, just going back to crop and just thinking about acreages. I think obviously acreage is down this year in the U.S. I've seen some early indications of acreages on corn going up sort of 5% or return to sort of very high levels. Is that how you're seeing it? And also some of your views on the soybean acreage development, which I think might be down a little bit, would also be very useful. The second question is just actually on the discontinuation of the Factor VIII gene therapy program. You know, does this represent a reprioritization away from gene therapy and maybe just on an update you could give us on the cell therapy around BlueRock Therapeutics would also be interesting. Thanks very much. All right, Richard. The first question is gonna be answered by Rodrigo, and then Stefan is going to talk about gene therapy and the Factor XI program. Richard, short answer would be that you are correct. We are seeing for the next year. It's too early, as you know, right? When you think about the commodity cycle that we have, also the adjustments that was done by the USDA in terms of yields for U.S. and the challenge that we have on the drought in Europe, there is a concern about supply of grains in the market. We foresee another positive cycle for commodities next year, what should lead to an acreage increase of corn, especially in U.S. because of comparing to this year. That's clearly soybeans, kind of the same, but I think corn is the main driver because of what happened this year in the U.S. We had almost like 4 million acres or 5 million acres less because of the weather conditions. We should see that happening next year. Aligning to that, my final comment, Richard, before I transition to Stefan here, is that we are seeing when you look to the order book, the demand for high technology, the best hybrids that we have in the portfolio, and the innovation that we have. That's a good indication when we see that of what we are foreseeing for the next season. Thank you for your question. Stefan. Yeah. Thanks, Rodrigo. Hi, Richard. To be very clear, the return of the rights to Ultragenyx for our DTX201 compound to treat hemophilia with gene therapy have nothing to do with reprioritizing our gene therapy. Quite to the contrary, we continue to be very happy with the progress of our clinical stage pipeline in gene therapy, mostly stemming from our AskBio acquisition. While this one goes back to Ultragenyx, and they now have back the full rights to the compound. Your question on cell therapy. What I can tell you is that we fully enrolled our phase I cohort for cell therapy in Parkinson's, and we're hoping to very soon give you the one-year data for the first cohort. Just to give you an idea, we should have this middle of next year for one year for the full cohort. We should have the data ready. More I cannot tell for now, but stay tuned. This is something that we feel extremely excited about. Thank you. We will take our next question. The next question comes from the line of Peter Verdult from Citi. Please go ahead. Your line is open. Thank you. Peter Verdult, Citi. Two questions. Just kicking off with Stefan. Just based on the current trajectory, when will Kerendia be a top 15 product Bayer? It just seems crazy that you're calling it out as contributing almost 50% of the division's growth, but not disclosing the sales. If you could give us some help here, Stefan, as to when, based on the current trajectory, Kerendia will be a top 15 product at Biopharma. Just now that the dust has settled on the Eylea 16-week data and you know what the competitors are saying, just what you think you can do with that asset in the ex-U.S. markets. It's just very obvious that the market cap change on the back of that data was stark between yourselves and your U.S. partner. Rodrigo, just come back to crop. Rather than ask you to repeat the same input that you've done for the last two questions, I suppose what it all comes down to is, you know, consensus for next year has low single-digit revenue declines, and a relatively modest margin impact. We're a little bit more aggressive to the downside, but just wanted to keep it tight and get a sense check from you, how comfortable or not you are given where expectations currently sit. Thank you. All right. Stefan is going to start, and then, Rodrigo will follow on. Thanks for the question, Peter. On Kerendia, yeah, we're very pleased with what we're seeing across the board. We're also gonna get going now in China after a really strong launch in the U.S. I'm sure you're tracking just like me, comparing this to other products in the category that have launched, and I think we're continuing to track at or above some comparables in the class. When will it hit the top products? Normally I don't guide in November for the following year, but we are also very confident for next year and then hope to give you a little bit more color, including in numbers. On Eylea 8 mg, we should get approval for this outside the U.S. by first quarter of 2024. This obviously is data that I think everyone who has looked at the data has seen that there is more than just life now in Eylea. This is unprecedented data with the dosing intervals which beats all published competitors to this day. We feel that this is going to give additional, let's say, life to this franchise above and beyond loss of exclusivity of the 2-mg formulation. Pete, let me take your question. We are already working, of course, in 2023. It's too early to set the guidance for next year. Let me use your question just to do one step back here, and just reinforce a little bit of my view about the market and our performance, right? We closed 2021 with a very strong performance above market. With the current results that we're seeing today, with a 17% sales growth on the first nine months of the year and the 30% EBITDA margin that we have, and when you look to the performance of the business, we are leading the business in corn, soybean, in herbicides, in biologicals, in digital and new frontiers like carbon. Clearly we are seeing that the performance of this year is a reinforcement of our mid long-term strategy and our investment on R&D, and the results of the innovation coming to the market. Of course, again, next year we're still working on that one. We had some vectors that we shared today here, but we cannot come back with a more precise answer for next year. Thank you. Thank you. We will take our next question. The next question comes from the line of Vincent Andrews from Morgan Stanley. Please go ahead. Your line is open. Thank you, and good morning, everyone. Rodrigo, just wondering if you could help us bridge the U.S. soybean performance this year with what you're anticipating next year. I guess in a couple of ways, if you could help us understand sort of what your volume and price mix was this year versus what you're anticipating with the double-digit price increase for next year. Do you think from a share perspective you're at the point now where you're gonna be able to defend the existing market share, or do you think you might get some back next year, or is there still risk of losing a little bit? I guess how much of that does it depend on XtendFlex? Oh, thank you, Vincent. Let me start with the end here. I think you nailed it, right? If you think for the entire group here on the call today, if you think about the last years, what happened is, of course, as Corteva transitioned their platform from our platform to Enlist, you could see an increase of the penetration of Enlist in the market. When it comes to the next years, we're gonna be a head-to-head competition, right? We'll depend a lot on the performance of the varieties in the market, and that's why we are confident about the next year that we're gonna compete in this market. We are still number one platform in the market with more than 50% of the market. Very important, as you said, this year we got to 20 million acres of XtendFlex. The new varieties, the precision breeding that we are seeing in the market is helping. Last year, we had a 2.5 bushels per acre advantage, and we are still collecting the data this year, but we are seeing very good results. What I would say is that, for the next years, we're gonna see a very head-to-head competition in the market, and we are confident on the plans that we have. Of course, preparing the launch for the next next-generation that you know, the HT4. Aside from that, I'll just use this question as well, Vincent, to reinforce about Latam, right? So when you think about soybean, LatAm, especially Brazil, became extremely important. We have more than 80% penetration in the market. We are moving to 6 million acres of Intacta 2 Xtend, and the performance is extremely solid as well there. More specific, when you look to the quarter of this year, you had an effect of the excess seed. That's basically also an impact that we saw on the numbers specifically about quarter. Confirming what you said, for the next years, we're gonna see a much more head-to-head competition and the importance of the varieties. The yield component in the market will play a big deal for the next years. Thank you. As a follow-up, could I just ask on the PCB litigation, the quarterly documents note that you filed a complaint in August, trying to enforce the rights under certain indemnification contracts. Could you just talk about sort of what the scope of that could be if you're successful and prevail on those? How much of the PCB liabilities could be covered under indemnification, and what is the timeframe you think to see whether you can get a court ruling in your favor on that? Yeah, Vincent. Thanks for the question. This is Werner speaking. First of all, we filed against all important so-called undertakers. These are our customers that gave us full recourse. With their commitment letters in the early 1970s, when they didn't have access to other products that were, in particular, fire retardant. With that, you know, that recourse that we have is not time-barred. It is open-ended and all-inclusive, and that's what we're pursuing. In terms of court, we don't have a perspective on that from a timing perspective. You know, this is a parallel process in terms of you're having a court proceeding and then of course, negotiations with each of the underwriters. Okay. Thank you very much. Appreciate it. Thank you. We will take our next question. The next question comes from the line of Laurent Favre from Exane BNP Paribas. Please go ahead. Your line is open. Thank you. Good afternoon. I only have one question left. It's for Rodrigo on the efficiency savings, EUR 200 million for 2022. I was wondering if you could share a number for 2023, please. Laurent, I'm sorry to say, but we're still working on that one. It's too early to say to give you a precise number. What I can tell that we are working with the organization on the efficiency programs that we have, also with the supply cost management that we are putting in place and in terms of supply resilience as well. When I think about the next two or three years working on the top line that we reinforce many times here today, but also on the bottom line and how we got those efficiencies in place, that's a very important element. Another thing that you saw in the market, the Environmental Science that was mentioned by Wolfgang, and if you look back a little bit, we also made some adjustments of our portfolio in Crop Science as well to drive higher margins for the future. I'll come back to that question early next year when we have the results of the Q4 as well. Thank you. Wolfgang, actually, you mentioned. Laurent, I can probably supplement for the audience just a tad bit as a reminder. If you recall, we had commissioned a program on efficiencies in 2020 that kicks in in 2023, 2024, 2025, and we said it would be EUR 1.5 billion plus. So from an overall modeling perspective, 2023, 2024, 2025, you can assume almost linearity for that. It's not precise yet. As Rodrigo said, we're working on the details, but I think it's important that you consider that when you do your longer term models. Sorry, you had a second question. Yeah, sorry. Wolfgang, you mentioned the impact of rebates on the free cash flow for this quarter compared to last year. I was wondering if the impact is mostly timing or are you adding to the rebates program to defend market share? Laurent, it's completely timing. Thank you. Thank you. We will take our next question. The next question comes from the line of Keyur Parekh from Goldman Sachs. Please go ahead. Your line is open. Hi. Thank you. Two questions if I may, please. The first one going to crop again. I'm just wondering how you guys are thinking about the split of planting between corn and soy kind of into the Northern Hemisphere next year. Any kind of early signs that obviously the lower 5 million acres this year kind of for corn creates an easier year-over-year comp, but any kind of signs or any sense you might be able to give us on how we should think of that split of broader corn versus soy next year. Then secondly, continuing with crop, just wondering how you guys are seeing kind of the market share dynamics kind of on kind of crop chemicals there. It seems like the volume growth kind of for the rest of your peers, including Corteva, that they reported kind of year-to-date seem to be a lot higher than what we're seeing from Bayer. Just wondering how you guys are thinking about volume in that part of the business. Thank you. Thank you, Keyur. Let me address the questions here and open to if any other comments as well from my peers here. In terms of corn, soybean, what I would say today for you is that when you combine the demand and also the supply, and I mentioned some of the challenge that we are seeing in terms of supply, in terms of yield, because of the weather conditions in Europe and a little bit of what happened in U.S., when we had the planting season here. I would say that there is trending more towards corn in increase next year versus soybean. We still see a soybean area that will be significant, but the trending, if I would give you an answer, is more towards corn. On the crop protection, volume, I would say that let's see by the closing of the fiscal year, because we have a lot of the dynamics of quarters and how they play the quarters in that market. We feel very good about our performance in herbicides, of course, this is, we are leading that market, and we are, with a very strong position in that one. But also, on fungicide side, where we hold the number two position and insecticide where we hold the number three position, we are seeing a lot of good development. We had launches that we did in the market, with the Adengo expansion and Fox family in Brazil that I think that the. When I look for the fungicide market, we are excited about the next year. That's probably one of the things that we are driving for us for the next year is the fungicide market, as you mentioned. Insecticides as well. We have just had a very important launch with Curbix that will be a major launch for us and we are expanding that in the market. Let me say to you that we have a very strong performance. For crop protection as well. We are managing in the market very low inventory in the channel because of the dynamics and the volatility that Wolfgang mentioned today in the call. Let's see. When we close this year, I would say that we are confident that we're gonna have a very good performance on crop protection as well. Thank you. Thank you. We will take our next question. The next question comes from the line of James Quigley from Morgan Stanley. Please go ahead. Your line is open. Hello. Thank you for taking my questions. Another one picking up on the Kerendia launch. The IMS data suggesting around $100 million or so for the first nine months of the year, with a big step up in September to about $23 million. Is this broadly in line with what you're seeing? Is there anything else we need to think about when tracking Kerendia launch via IMS? I think Werner mentioned the guideline changes that you got for Kerendia as well earlier or a couple of weeks back. To what extent will these be incremental? Were doctors using Kerendia on top of SGLT-2s anyway, or is this gonna be another sort of pocket of upside for the launch? Then when I think about the Consumer business, and you mentioned again the Rx-to-OTC switches and Astepro has been a success and you're looking to do this again, how many potential Rx-to-OTC switches do you have in the pipeline? When can they launch? And typically, what would you say is a growth impact in the year of a launch for Rx-to-OTC switches from what you've seen in your business historically? Thank you. All right, James. Stefan will start and then, Heiko is going to take the OTC switch question. Yeah. First, I don't know if I can really respond to your first question. Because there's a gross-to-net in the middle, I will neither confirm nor deny because otherwise I would be making a forward-looking statement for the year. Again, I think you're right. You're seeing, we're seeing the TRx uptick, which is really nice, coming out of the U.S. Again, China should be following suit soon. For this year, overall, let's say you're not that far away. The SGLT-2 question, James, can you please say this again, what you needed exactly on the SGLT-2 opportunity? It's just from what you're seeing so far, are doctors already using Kerendia on top of SGLT-2s? Or how is the guideline changes from KDIGO, is that incremental in terms of suggesting or allowing or recommending combination use of Kerendia and SGLT-2s? I mean, we're seeing now in all the guidelines, not just the KDIGO guidelines, we're seeing also from ADA and other guidelines, we're seeing now Kerendia very prominently placed, that you would put it on top of SGLT-2, makes good sense. If SGLT-2 is already used in the base case to treat diabetes. My understanding is that if you're not using SGLT-2 as a baseline and want to treat kidney ailment, you can directly go with Kerendia also under this guideline. We're seeing that we're really making good headroom and becoming a foundational treatment for kidney patients. We're seeing in our existing base a good number of patients on SGLT-2 that you add Kerendia to it. We're seeing also many patients that are not on SGLT-2 yet that are getting early on onto Kerendia. Note that when you take type 2 diabetes, the vast majority of diabetics being treated and that develop kidney disease are not currently treated with SGLT-2. We think that both in combination as well as a foundational therapy for kidney, we're well-placed. That's also at least how I read the guidelines, very, very nicely covered by the guidelines. What you have to note is that now all major colleges out there, physician colleges are recommending the use of Kerendia in a very broad patient population. Okay, just a couple of comments on the Rx-to-OTC switches. Indeed, we really like them for a couple of reasons. It really brings true innovation to Consumer Health. You know, our customers love it because it expands the size of their categories. Of course for consumers, it's very beneficial because they tend to be superior propositions, as we also see with our Astepro launch. So it really gives good incremental innovation. The last reason why we particularly like it at Bayer is that because we think we have competitive skills there that not everyone has. To bring such a product from Rx-to-OTC, you need to have good understanding of regulatory processes and dealing with that, getting approval from the FDA in this case, which is a U.S. launch. You need to understand how to do those. This is not so easy. Not everyone is able to successfully execute those. We think that we have a very good team there. Obviously we are therefore not planning to limit this only to Astepro. We are working actually on a pipeline. I don't want to now start to give you the full detail of all the things that we're planning in the innovation in the coming years. Obviously, we will release those once we can, once this is competitively the right time to do that. Clearly it will remain an important part of our strategy. In this quarter, we saw it immediately. It immediately delivered in allergy double-digit growth. It's very incremental. It also comes with quite some investment of course, because these are usually new brands. As it is a new active ingredient, we have to create a new brand name. Launching a new brand name in the U.S. is not cheap, but it's worth the investment. The ROIs are very good on it, and it's true innovation that I think consumers are expecting from Bayer in this category. Okay. Thank you very much. Thank you. We will take our next question. The next question comes from the line of Sachin Jain from Bank of America. Please go ahead. Your line is open. Hi there. Thanks for taking my questions. A couple, please. Firstly, when you were in your introductory comments referring to guidance there, I think you said pharma guidance may be a challenge with upside in crop. So I wonder if you could just give us a bit more detail on where you see the challenges in that pharma guidance. I'm assuming it's on the margin front, and therefore do those pressures persist into next year? Mm-hmm. Secondly, chance my arm on the glyphosate pricing. When you're talking normalization, could you give us any directional commentary as to where you think that ends up in 2023, and how we should think about 2023 glyphosate pricing versus the EUR 2.1 billion-EUR 2.2 billion, I guess you end up for this year? Final question is on PCB, slightly different tack, for Werner, like with the earlier question. What are the pivot points for you in considering whether you need to provide additional provisions for this relative to what you've already taken, given, since the second quarter call, additional states and some personal injury claims that have come through? Thank you very much. All right, Sachin, this is Werner. Good morning and thanks for your three questions. First of all, I mean, when it comes to where the challenges are for the guidance, it's clear that for pharma, it's a margin challenge. You can see that already. We are, you know, quite a bit stretched based on the effects that I mentioned earlier. On top of that, we have a few other things that we touched on, e.g., the continued difficult environment for pharma in China, where normal commercial activities are not possible. As a matter of fact, I was in Beijing just about, you know, three days ago, and it's very different from, let's say, a normal environment there. People cannot, you know, operate normally, and that also holds true for our commercial organization. Given the significance of our China business, that of course has an impact. Secondly, we have a disproportionately high FX impact on our Pharma business. You know, that weighs also heavily on the margin profile, which means we get the inflationary, quote-unquote, expansion of the top line, but have substantially less of that in the bottom line, actually even to the extent that it's negative, for example, for the quarter. That weighs on the Pharma business. Now, Rodrigo already said that we are 17% year-to-date, top line up, and with another quarter to come, you know, there's, let's say the perspective of that quarter that could even be a little bit better. We have not, you know, adjusted for it because in the grand scheme of things, it wouldn't have changed the guidance for the company. So that's all that's to be said for pharma and crop. Your takeaway should be that, you know, for the company it doesn't make a difference, but the composition of the delivery is gonna be slightly different potentially. On glyphosate normalization, we don't see that your prices will come down to the levels that we saw end of 2020, early into 2021, because cost has increased for generic manufacturers. Logistic cost is sky high, which would always be your major driver in terms of what the cost base is for our competitors. We of course do have the advantage of being vertically integrated for our Glyphosate business. But having said that, going into 2023, we do not expect that you know the average pricing will be anywhere near what we are seeing in 2022. Yeah. The easiest for you is to look at the generic glyphosate pricing curve, where it's averaging out in 2022, and then you just take end of quarter three and you're going into quarter four, what you see there as a good proxy. We are, you know, we are entering the year and that's the base that we are going to use also to, you know, provide a frame for the budget and revisit the guidance. We are not there yet, as Rodrigo already pointed out. When it comes to PCB, you know, we have, for all provisions, we have a quarterly review. Each quarter we look at whether the level of provisioning for the known cases and the perspective on those, and whether some of these have materialized to or matured to an extent that we can reliably estimate whether there's an exposure or not, then there would be an adjustment. Yeah. From today's perspective, we are just about talking about the closing of quarter three, there's nothing that would have to be provided for early on. On the personal injury case, yes, we have three more with a new suit, but it's very, very early on, so there's nothing that we could say there. Then last but not least, also latching onto my prior answer on recourse. In the accounting world, you know, we have to provide for exposures that are more likely than not to occur. Yeah. Which means they are higher than 50% likelihood of occurrence of an exposure. We are going to put a provision on the book with a few more criteria to be met. When it comes to recourse. We haven't booked anything because on the side of, let's say, accounts receivable for any claim that we have, the level of it, the standard is much higher, which means it has to be virtually certain that what we put on the books. Even though we are very confident that something good is going to come out of it for us, we cannot book anything at this point in time, which means from a timing perspective, it would always be disparate between what it is that we book early on, which is the exposure, and then recovery would come later. Very okay. Thank you very much, Werner. All right. My pleasure. Thank you. Heidi, I'm conscious of time. I think there's max time for two more questions. Of course, we will take our next question. The next question comes from the line of Dominic Lunn from Credit Suisse. Please go ahead. Your line is open. Thank you very much. Just on inflation again. I think you said about EUR 1.3 billion impact year to date, but how much specifically was in Q3? Presumably, this should be about the minimum guide for the next few quarters. Then secondly, on Nubeqa, if we look to the U.S. NBRx numbers, and this has really taken off in recent weeks, and presumably this translates to sales over time. I just wanted to get your thoughts on what's driving this apparent step change in utilization. Because I know, you know, previously you talked about ARASENS maybe being more of a marketing tool to help you get the full range of prostate indications, but, you know, has this actually exceeded your own internal expectations, or is there anything else you'd point to? Yeah, Dominic, I can take the first one on the inflation. We're not spelling it out quarter by quarter, but you can assume that Q3 was bigger than Q2, and Q2 was bigger than Q1. That going forward, rather than seeing less, we see a bit more because of the mentioned inventory effects, because some of it is still sitting in inventory. You saw the increases there quarter-over-quarter. It will go up from here before it then will hopefully go down in the future. Well, on Nubeqa, I think you have it. I mean, the extension of the indication now allows us to more broadly communicate around the use of Nubeqa. That translates into more use. Let's not forget that we launched this product very successfully in the middle of a pandemic with very limited field resources. So those are pretty much back online. I think it's coming through now that this is also converting into uptake in prescription. So we're super pleased. I couldn't say that we didn't expect it because we knew that we had a best-in-class product here, and I think the evidence shows it, and it's now coming through in the prescription as well. So this is. We're very, very pleased with the Nubeqa performance. Great. Thank you very much. Thank you, Dominic. Thank you. We will take our final question. The final question comes from the line of Falko Friedrichs from Deutsche Bank. Please go ahead. Your line is open. Thanks very much. Good afternoon. Two questions, please. Firstly, on your Consumer Health business and especially the Nutritionals part, do you think there is a risk of a potential slowdown over the next quarters in light of this whole inflation pressure on income levels, or do you think it should be relatively robust? Secondly, on your free cash flow guidance increase of about EUR 500 million due to lower net settlement payments, can you share a bit more color here why those settlement payments were lower than you initially expected this year? Thank you. Hi, Falko. Heiko is going to take the first one, and then Wolfgang is going to shed some light on the free cash flow. Yeah. We've seen already now Nutritionals slowing down a bit in terms of the growth versus, of course, a very high growth in the year before and also the year before that. I would kind of say that we've kind of reached a new normal now there. It just has landed on a very high level. I don't expect it now to sort of dramatically come down. I don't think we should assume that. I think some of these habits that have been formed over the past two years in the post-COVID world where people are starting to take better care of their personal health are still there. I think people are also worried about their immune system as we go forward because immunity has been the main driver behind that. I think supplementation is still a very good space to be. When we look across the board now with the effects of quite significant pricing that is, of course, being taken across the industry, we don't observe a sudden spike in private label growth because we are tracking that very closely. We clearly see that on a quarterly basis, we're checking in with consumers. They clearly tell us that their health remains number one priority, and that how they're dealing then with the price increases is in some shape or form, they're looking for better deals, of course, out there. We see that some move to a bit smaller packs or value packs. That's why there could be, you see a bit of impact on the volume side. Frankly, I'm not overly concerned about it. I think we are in a good spot with that category because the underlying consumer habits are very solid around supplementation still. I hope that answers your question. Yeah. Falko, a quick one on the free cash flow. Yes, you're correct. The improvements to the free cash flow do indeed come from reduced payouts for settlements. We started the year with an assumption of about EUR 2.5 billion. We now have penciled it in at EUR 2 billion. Year to date, for three quarters, we were like EUR 1.1 billion-EUR 1.2 billion. We'll see how that goes. It could be a little bit more free cash. It could be that we pay a little bit less than that. The improvement clearly comes from the glyphosate complex. Obviously, I think you can appreciate this, with five wins under our belt, we are in no particular rush either on the current or on starting the futures program. We review that as we go and focus on winning more cases. Okay. Thank you. Thank you, Falko. I think that was the last question. I was waiting for Heidi. So sorry. Thanks to all for your time and attention today. It's greatly appreciated, as always. This closes our call for the third quarter. Thank you, everybody. Talk soon. This concludes today's conference call. Thank you for participating. You may now disconnect.